Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer
NCT05963087
·
clinicaltrials.gov ↗
NA
Phase
NOT_YET_RECRUITING
Status
22
Enrollment
OTHER
Sponsor class
Conditions
Advanced Colorectal Cancer
Interventions
DRUG:
Cetuximab Dabrafenib Tislelizumab
Sponsor
Zhejiang Cancer Hospital